摘要
目的探讨非小细胞肺癌(NSCLC)患者中表皮生长因子受体(EGFR)基因的突变情况,并研究EGFR基因突变和肿瘤标志物水平的相关性。方法实时荧光定量PCR法(ARMS法)检测患者肿瘤组织中EGFR基因突变情况,电化学发光免疫法测定患者血清肿瘤标志物水平,并分析EGFR基因突变情况与血清肿瘤标志物水平关系。结果 48例NSCLC患者中有24例(50%)存在EGFR基因突变。NSCLC患者的EGFR突变阳性率与性别、吸烟史及血清肿瘤标志物CYFRA21-1、CA125水平具有相关性,进一步分析显示19外显子突变阳性的患者血清CEA水平较21外显子突变阳性和突变阴性患者明显增高。结论肿瘤标志物CA125、CYFRA21-1变化可能与EGFR基因突变相关,且血清CEA水平与EGFR突变类型相关;CA125、CYFRA21-1和血清CEA水平可以作为潜在判定靶向治疗疗效的血清学指标,值得临床进一步研究。
Objective To investigate the epidermal growth factor receptor（EGFR） gene mutations in non small-cell lung cancer（NSCLC） patients,and study the correlation between EGFR gene mutations and tumor markers. Methods Real-time fluorescent quantitative PCR method（ARMS assay） was applied to detect the EGFR gene mutations in tumor tissues of NSCLS patients,and ECLI was used to measure the levels of serum tumor markers. The relationship between EGFR gene mutation and serum tumor markers level was analyzed in these NSCLC patients. Results EGFR mutations were found in half of the NSCLC patients（24/48）. EGFR gene mutations were correlated with sex,smoking status and serum level of CYFRA21-1,CA125（P〈0.05）. In addition,the serum CEA level was higher in patients with mutations at exon 19 than those with mutations and without mutations at exon 21. Conclusion The changes of CAl25 and CYFRA21-1 may be related to the gene mutation of EGFR,and serum CEA level is related to the EGFR mutation types. CAl25,CYFRA2l-1 and serum CEA level can be used as potential serological indicators of target therapy efficacy,worthy of further clinical study.
出处
《中国卫生检验杂志》
北大核心
2014年第15期2217-2219,2222,共4页
Chinese Journal of Health Laboratory Technology
